Is Anthera Pharmaceuticals Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Anthera Pharmaceuticals Inc (ANTH) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Anthera Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Anthera Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Anthera Pharmaceuticals Inc?

Muslim investors may consider investing in Anthera Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Anthera Pharmaceuticals Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Anthera Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Anthera Pharmaceuticals Inc updated?

The Shariah compliance status of Anthera Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Anthera Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Anthera Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Anthera Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Anthera Pharmaceuticals Inc. Stock Analysis ANTH

United States Health Care Nano Cap

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Key Statistics of Anthera Pharmaceuticals Inc (ANTH)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

5325.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

5236.00

Avg. Volume

15.37K

Dividend Yield

Financial Metrics & Statements of Anthera Pharmaceuticals Inc (ANTH)

FAQ's for Anthera Pharmaceuticals Inc (ANTH)

According to Musaffa’s Shariah screening methodology, Anthera Pharmaceuticals Inc (ANTH) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.